|Bid||6.2300 x 700|
|Ask||6.2400 x 1400|
|Day's range||6.2200 - 6.3600|
|52-week range||5.2800 - 9.8600|
|PE ratio (TTM)||-5.80|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||11.71|
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Jim Cramer rattles off his take on caller favorite stocks, including these two energy players that could be competing for business.